← Evidence map

ArticlePancreas2020

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial: Erratum.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial: Erratum. | OpenQuestion